We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




New Findings May Lead to Enhanced Treatments for Multiple Sclerosis and Autoimmune Inflammation

By LabMedica International staff writers
Posted on 10 Dec 2014
Print article
A multidisciplinary research team of scientists from Singapore has made a breakthrough discovery of a new type of immune cells that may help in the development of a future treatment for multiple sclerosis (MS).

Led by Prof. Xin-Yuan Fu, senior lead investigator from CSI Singapore and professor at the department of biochemistry at the National University of Singapore (NUS) Yong Loo Lin School of Medicine (Singapore), and Dr. Wanqiang Sheng, postdoctoral fellow at CSI Singapore, the scientists discovered that a new type of immune T helper cells called TH-GM cells play a crucial role in the immune system and pathogenesis of neuronal inflammation. The findings offer insights into a potential new avenue for therapeutic intervention, which can be used independently or combined with other treatment options to optimize outcomes in the treatment of MS.

Working with Dr. Yong-Liang Zhang, from the department of microbiology at the NUS Yong Loo Lin School of Medicine, Prof. Fu and his team demonstrated that STAT5, a member of the STAT family of proteins, programs TH-GM and triggers the immune response to an autoantigen in responding to a signal from an interleukin, IL-7, causing neuroinflammation, pathogenesis and damage in the central nervous system. Blocking IL-7 or STAT5 would provide a substantial therapeutic benefit for this disease. The study’s findings were published online November 21, 2014, in the journal Cell Research.

MS is the most prevalent autoimmune disease of the central nervous system, affecting about 2.5 million people worldwide, with cases showing a higher prevalence in Northern Europe. In spite of many years of research, the causes of MS are mostly not known and the disease remains incurable.

This study provides vital clues into the processes behind MS. Dr. Richard Flavell, chair of the department of immunology at Yale University (New Haven, CT, USA), and a world leader in the immunology field, noted that the findings from the study may now provide a mechanistic link between IL-7/STAT5-mediated signaling and T helper cell-mediated pathogenicity.

The STAT family of proteins and their signaling pathway (called JAK-STAT) were first discovered by Prof. Fu and his colleagues in 1992. Disturbance of this pathway was shown to be a major cause for many kinds of inflammatory disorders. Innovative drugs interfering with JAK-STAT have since been approved in the United States, Europe, and Singapore for the treatment of numerous diseases, and annual sales of medicines involving JAK-STAT are expected to exceed USD 1.6 billion in 2016. The newly discovered IL-7-STAT5 by Prof. Fu and his team in neuroinflammation considerably expands this line of medical research, development, and therapeutic intervention in a variety of major diseases.

Prof. Fu and collegues are now researching the physiologic function of TH-GM to further the development of therapy for various human autoimmune diseases.

Related Links:

CSI Singapore
National University of Singapore Yong Loo Lin School of Medicine


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Specimen Collection & Transport
POCT Fluorescent Immunoassay Analyzer
FIA Go
New
Gold Member
Fully Automated Cell Density/Viability Analyzer
BioProfile FAST CDV

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Molecular Diagnostics

view channel
Image: The study showed the blood-based cancer screening test detects 83% of people with colorectal cancer with specificity of 90% (Photo courtesy of Guardant Health)

Blood Test Shows 83% Accuracy for Detecting Colorectal Cancer

Colorectal cancer is the second biggest cause of cancer deaths among adults in the U.S., with forecasts suggesting 53,010 people might die from it in 2024. While fewer older adults are dying from this... Read more

Hematology

view channel
Image: The Gazelle Hb Variant Test (Photo courtesy of Hemex Health)

First Affordable and Rapid Test for Beta Thalassemia Demonstrates 99% Diagnostic Accuracy

Hemoglobin disorders rank as some of the most prevalent monogenic diseases globally. Among various hemoglobin disorders, beta thalassemia, a hereditary blood disorder, affects about 1.5% of the world's... Read more

Microbiology

view channel
Image: The new platform is designed to perform blood-based diagnoses of nontuberculosis mycobacteria (Photo courtesy of 123RF)

New Blood Test Cuts Diagnosis Time for Nontuberculous Mycobacteria Infections from Months to Hours

Breathing in nontuberculous mycobacteria (NTM) is a common experience for many people. These bacteria are present in water systems, soil, and dust all over the world and usually don't cause any problems.... Read more

Industry

view channel
Image: These new assays are being developed for use on the recently introduced DxI 9000 Immunoassay Analyzer (Photo courtesy of Beckman Coulter)

Beckman Coulter and Fujirebio Expand Partnership on Neurodegenerative Disease Diagnostics

Beckman Coulter Diagnostics (Brea, CA, USA) and Fujirebio Diagnostics (Tokyo, Japan) have expanded their partnership focused on the development, manufacturing and clinical adoption of neurodegenerative... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.